Comparison of In-vitro Activities of Linezolid and Vancomycin Against Staphylococcus Aureus Isolated from A Tertiary Care Hospital

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2014 Jul 5

PMID 24995175

Citations 5

Authors

Sachin Kishore

Deepika Verma

Me Siddique

Affiliations

Soon will be listed here.

Abstract

Background: Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the commonest cause of hospital acquired infections worldwide. Vancomycin is the antibiotic of choice for treatment of MRSA, but due to slow increase in vancomycin minimum inhibitory concentration (MIC) (vancomycin creep),Vancomycin has become a suboptimal therapeutic option in critically ill patients. Linezolid has emerged as an alternative drug in the treatment of such cases.

Aim: To compare in vitro activities of linezolid and vancomycin against Staphylococcus aureus, in order to help in formulating a better treatment.

Method: 200 strains of Staphylococcus aureus were isolated from different clinical specimens between April 2010 to March 2011. Antibiotic sensitivity testing was performed by Kirby Bauer disc diffusion method and MICs of vancomycin and linezolid were determined for all 200 strains by agar dilution method by following CLSI guidelines.

Results: Among 200 strains, MIC for linezolid was 4 μg/ml for 3 strains, MIC was 2 μg/ml for 71 strains, and MIC was 1 μg/ml for 126 strains, while for the same 200 strains of Staphylococcus aureus, MIC of vancomycin was 4 μg/ml for 8 strains, it was 2 μg/ml for 103 strains and it was 1 μg/ml for 89 strains.

Conclusion: Linezolid and vancomycin had similar in-vitro efficacies for Staphylococcus aureus in disc diffusion method, but the number of strains with higher ranges of MICs of vancomycin (1-4 μg/ml) were more as compared to those which had higher ranges of MICs for linezolid. So, we suggest that linezolid can be a good alternative for the treatment of multidrug resistant Staphylococcus aureus as compared to vancomycin.

Citing Articles

Induced Wound Infections Which Antimicrobial Resistance, Methicillin- and Vancomycin-Resistant: Assessment of Emergence and Cross Sectional Study.

Almuhayawi M, Alruhaili M, Gattan H, Alharbi M, Nagshabandi M, Al Jaouni S Infect Drug Resist. 2023; 16:5335-5346.

PMID: 37605760 PMC: 10440082. DOI: 10.2147/IDR.S418681.

Exploring novel aryl/heteroaryl-isosteres of phenylthiazole against multidrug-resistant bacteria.

Omara M, Hagras M, Elsebaie M, Abutaleb N, Nour El-Din H, Mekhail M RSC Adv. 2023; 13(29):19695-19709.

PMID: 37425632 PMC: 10323310. DOI: 10.1039/d3ra02778c.

Sustained release of linezolid in ocular insert based on lipophilic modified structure of sodium alginate.

MohammadSadeghi A, Farjadian F, Alipour S Iran J Basic Med Sci. 2021; 24(3):331-340.

PMID: 33995944 PMC: 8087856. DOI: 10.22038/ijbms.2021.49866.11385.

Phenotype-Genotype Characterization and Antibiotic-Resistance Correlations Among Colonizing and Infectious Methicillin-Resistant Recovered from Intensive Care Units.

Nour El-Din H, Yassin A, Ragab Y, Hashem A Infect Drug Resist. 2021; 14:1557-1571.

PMID: 33907431 PMC: 8071083. DOI: 10.2147/IDR.S296000.

Characterization of Staphylococcus aureus from Humans and a Comparison with İsolates of Animal Origin, in North Dakota, United States.

Velasco V, Buyukcangaz E, Sherwood J, Stepan R, Koslofsky R, Logue C PLoS One. 2015; 10(10):e0140497.

PMID: 26484768 PMC: 4618867. DOI: 10.1371/journal.pone.0140497.

References

Loomba P, Taneja J, Mishra B . Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients. J Glob Infect Dis. 2010; 2(3):275-83. PMC: 2946685. DOI: 10.4103/0974-777X.68535. View

Clemett D, Markham A . Linezolid. Drugs. 2000; 59(4):815-27; discussion 828. DOI: 10.2165/00003495-200059040-00007. View

Wang G, Hindler J, Ward K, Bruckner D . Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006; 44(11):3883-6. PMC: 1698298. DOI: 10.1128/JCM.01388-06. View

Kaleem F, Usman J, Khalid A, Hassan A, Omair M . Comparison of in vitro efficacy of linezolid and vancomycin by determining their minimum inhibitory concentrations against methicillin resistant Staphylococcus aureus (MRSA). J Pak Med Assoc. 2011; 61(4):356-9. View

Zurenko G, Yagi B, Schaadt R, Allison J, Kilburn J, Glickman S . In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996; 40(4):839-45. PMC: 163216. DOI: 10.1128/AAC.40.4.839. View

Thool V, Bhoosreddy G, Wadher B . Detection of resistance to linezolid in Staphylococcus aureus infecting orthopedic patients. Indian J Pathol Microbiol. 2012; 55(3):361-4. DOI: 10.4103/0377-4929.101745. View

Gupta N, Saini S, Kumar B, Arora D . In vitro activity of linezolid in Staphylococcus aureus. Indian J Med Microbiol. 2007; 21(4):289-90. View

Ikeda-Dantsuji Y, Hanaki H, Nakae T, Takesue Y, Tomono K, Honda J . Emergence of linezolid-resistant mutants in a susceptible-cell population of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(5):2466-8. PMC: 3088184. DOI: 10.1128/AAC.01548-10. View

Rajaduraipandi K, Mani K, Panneerselvam K, Mani M, Bhaskar M, Manikandan P . Prevalence and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus: a multicentre study. Indian J Med Microbiol. 2006; 24(1):34-8. DOI: 10.4103/0255-0857.19892. View

10.

. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern. Indian J Med Res. 2013; 137(2):363-9. PMC: 3657861. View

11.

Srinivasan S, Sheela D, Mathew R, Bazroy J, Kanungo R . Risk factors and associated problems in the management of infections with methicillin resistant Staphylococcus aureus. Indian J Med Microbiol. 2006; 24(3):182-5. View

12.

Howden B, Ward P, Charles P, Korman T, Fuller A, du Cros P . Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004; 38(4):521-8. DOI: 10.1086/381202. View

13.

Shinabarger D, Marotti K, Murray R, Lin A, Melchior E, Swaney S . Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 1997; 41(10):2132-6. PMC: 164082. DOI: 10.1128/AAC.41.10.2132. View

14.

Swenson J, Tenover F . Results of disk diffusion testing with cefoxitin correlate with presence of mecA in Staphylococcus spp. J Clin Microbiol. 2005; 43(8):3818-23. PMC: 1233887. DOI: 10.1128/JCM.43.8.3818-3823.2005. View

15.

Price J, Atkinson S, Llewelyn M, Paul J . Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis. 2009; 48(7):997-8. DOI: 10.1086/597359. View

16.

Tiwari H, Sen M . Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis. 2006; 6:156. PMC: 1634751. DOI: 10.1186/1471-2334-6-156. View

17.

Chaudhury A, Kumar A . In vitro activity of antimicrobial agents against oxacillin resistant staphylococci with special reference to Staphylococcus haemolyticus. Indian J Med Microbiol. 2007; 25(1):50-2. DOI: 10.4103/0255-0857.31062. View

18.

Tandel K, Praharaj A, Kumar S . Differences in vancomycin MIC among MRSA isolates by agar dilution and E test method. Indian J Med Microbiol. 2012; 30(4):453-5. DOI: 10.4103/0255-0857.103768. View

19.

Sarma J, Ahmed G . Characterisation of methicillin resistant S. aureus strains and risk factors for acquisition in a teaching hospital in northeast India. Indian J Med Microbiol. 2010; 28(2):127-9. DOI: 10.4103/0255-0857.62489. View